Palleos Healthcare GmbH
Adriamycin(Palleos Healthcare GmbH)은 Hodgkin Lymphoma 표적 ADC로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 95% (ClinicalTrials.gov NCT03677141). PK: t½ 78.4 days. 차별점: novel nitro-benzimidazole derivatives in luminal and Adriamycin-resistant breast cancer cell lines.
Hodgkin Lymphoma
Multiple Myeloma
Active
vedotin, vinblastine, and dacarbazine)
Lipid Nanoparticles Loaded with Bcl-2 siRNA and Doxorubicin and Their Targeted Therapeutic Effect
novel nitro-benzimidazole derivatives in luminal and Adriamycin-resistant breast cancer cell lines
target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway
T cell activation
apoptosis and cell cycle distribution, fluorescence-based morphological analyses, and gene-metabolite interaction analysis
biomarkers in serum, besides histopathological alterations in rats' liver and kidney
resistance to anthracycline-based chemotherapy remains a major clinical challenge
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Palleos Healthcare GmbH
Adriamycin(Palleos Healthcare GmbH)은 Hodgkin Lymphoma 표적 ADC로, Multiple Myeloma 영역에서 개발·상용화 중입니다. 작용기전: target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 95% (ClinicalTrials.gov NCT03677141). PK: t½ 78.4 days. 차별점: novel nitro-benzimidazole derivatives in luminal and Adriamycin-resistant breast cancer cell lines.
Hodgkin Lymphoma
Multiple Myeloma
Active
vedotin, vinblastine, and dacarbazine)
Lipid Nanoparticles Loaded with Bcl-2 siRNA and Doxorubicin and Their Targeted Therapeutic Effect
novel nitro-benzimidazole derivatives in luminal and Adriamycin-resistant breast cancer cell lines
target multiple pathways, including adenosine triphosphate(ATP) binding, endoplasmic reticulum function, the mitogen-activated protein kinase(MAPK) pathway
T cell activation
apoptosis and cell cycle distribution, fluorescence-based morphological analyses, and gene-metabolite interaction analysis
biomarkers in serum, besides histopathological alterations in rats' liver and kidney
resistance to anthracycline-based chemotherapy remains a major clinical challenge
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.